Published in final edited form as:

J Org Chem. 2006 January 6; 71(1): 142–149. doi:10.1021/jo0518809.

Regioselective Copper-Catalyzed Amination of Chlorobenzoic Acids: Synthesis and Solid-State Structures of *N*-Aryl Anthranilic Acid Derivatives

Xuefeng Mei, Adam T. August, and Christian Wolf*

Department of Chemistry, Georgetown University, Washington, DC 20057

Abstract

A chemo- and regioselective copper-catalyzed cross-coupling reaction for effective amination of 2-chlorobenzoic acids with aniline derivatives has been developed. The method eliminates the need for acid protection and produces a wide range of *N*-aryl anthranilic acid derivatives in up to 99%. The amination was found to proceed with both electron-rich and electron-deficient aryl chlorides and anilines and also utilizes sterically hindered anilines such as 2,6-dimethylaniline and 2-*tert*-butylaniline. The conformational isomerism of appropriately substituted *N*-aryl anthranilic acids has been investigated in the solid state. Crystallographic analysis of seven anthranilic acid derivatives showed formation of two distinct supramolecular architectures exhibiting *trans-anti*- and unprecedented *trans-syn*-dimeric structures.

Introduction

Cross-coupling reactions resulting in carbon-heteroatom bond formation have received increasing attention in recent years.¹ Significant progress has been reported for Pd-catalyzed amination reactions proceeding with aryl halides under mild conditions.² Alternatively, copper-mediated cross-coupling reactions utilizing anilines,³ amides,⁴ imidazoles⁵ and other heterocycles,⁶ β -amino alcohols,⁷ and aliphatic amines have also been developed.⁸

Copper-mediated amination of 2-chlorobenzoic acid was first accomplished by Ullmann.⁹ Since then, various efforts to improve the efficiency of this reaction involving the use of ultrasound-assisted methods have been reported.¹⁰ We have recently reported a copper-catalyzed amination protocol for the synthesis of substituted *N*-aryl anthranilic acids, which were further utilized as precursors for ring construction of 9-chloro- and 9-bromoacridines.¹¹ *N*-Aryl anthranilic acids, such as flufenamic and mefenamic acid, are important non-steroidal anti-inflammatory drugs (NSAIDs) and promising candidates for the therapy of neurodegenerative and amyloid diseases (Figure 1).¹² They are also important precursors for the synthesis of substituted acridines which have been used as antimalarial and anticancer drugs.¹³ Buchwald et al. developed an effective Pd-catalyzed amination procedure that is applicable to aryl chlorides with free carboxylic acid groups in *meta*- or *para*-position.¹⁴ A complementary copper-catalyzed amination reaction that proceeds with *ortho*-chlorobenzoic acid albeit with only moderate yields has been reported.¹⁵ As a result, *N*-aryl anthranilic acid derivatives are usually prepared through Ullmann-Jourdan reaction or Buchwald-Hartwig amination with alkyl 2-iodobenzoates and subsequent hydrolysis.¹⁶ We wish to report a general synthetic procedure providing substituted *N*-aryl anthranilic acids in high to excellent yields via Cu-catalyzed amination of *ortho*-chlorobenzoic acids. Through isothermal

evaporation, we were able to obtain single crystals of a series of *N*-aryl anthranilic acid derivatives. Crystallographic analysis revealed two distinctive packing motifs exhibiting either a *syn*- or an *anti*-arrangement of anthranilic acid dimers which are stabilized by two centrosymmetric C=O...H-O hydrogen bonds. The unprecedented interdependence of the dimeric arrangement and crystal structure of substituted anthranilic acids is closely related to supramolecular conformational isomerism.

Results and Discussion

For initial screening of suitable reaction conditions, we decided to study formation of *N*-(2-methylphenyl)anthranilic acid, **3**, from 2-chlorobenzoic acid, **1**, and 2-methylaniline, **2**, through copper-catalyzed amination using potassium carbonate as the base and 2-ethoxyethanol as solvent. The desired anthranilic acid **3** was obtained in moderate yields with catalytic amounts of CuI, Cu₂O or Cu (Table 1, entries 1–3). However, results improved significantly in the presence of both Cu and Cu₂O and **3** was produced in 71% and 76% after 5 and 24 hours, respectively (Table 1, entries 5 and 7). Variation of the Cu/Cu₂O-ratio and replacement of Cu₂O by CuI did not further increase yields (Table 1, entries 4, 6–9).

We then decided to study the effect of solvent and base on the amination reaction. Anthranilic acid **3** was obtained in 75% and 76%, respectively, using Cu/Cu₂O as the catalyst in *n*-butanol or 2-ethoxyethanol in the presence of two equivalents of potassium carbonate, while only poor yields were obtained in water and ethylene glycol (Table 2, entries 1–4). We were pleased to find that yields of **3** could be enhanced to 90% when diethylene glycol or 2-ethoxyethanol was used as the solvent (Table 2, entries 5 and 12). The Cu/Cu₂O-catalyzed amination of 2-chlorobenzoic acid proved to depend significantly on the base employed. Comparison of the results obtained with Na₂CO₃, Cs₂CO₃, K₃PO₄, NaOAc, *tert*-BuOK, and 2,2,6,6-tetramethylpiperidine (TMP) shows that yields of **3** obtained in diethylene glycol vary from 5–90% (Table 2, entries 5–11). We found that anthranilic acid **3** was produced in only 5–30% in the presence of cesium carbonate, 2,2,6,6-tetramethylpiperidine and *tert*-BuOK (Table 2, entries 6, 8 and 11). By contrast, anthranilic acid **3** was formed in 90% and 82% through Cu/Cu₂O-catalyzed amination of **1** with **2** using K₂CO₃ or Na₂CO₃ in diethylene glycol (Table 2, entries 5 and 7). We also observed that the amination proceeds with excellent yields with one equivalent of sodium or potassium carbonate in 2-ethoxyethanol (Table 2, entries 12–14).

The copper-catalyzed C-N bond formation procedure was then applied to a variety of aryl amines and chlorobenzoic acids to produce a series of *N*-arylanthranilic acids (Table 3). We found that the presence of one bulky *ortho*-substituent does not impede effective amination (Table 3, entries 2–5). For example, 2-*tert*-butylaniline, **8**, and 2-phenylaniline, **10**, gave *N*-(2-*tert*-butylphenyl)anthranilic acid, **9**, in 86% and *N*-(2-biphenyl)anthranilic acid, **11**, in 85% yield (Table 3, entries 4 and 5). Incorporation of two *ortho*-substituents to aniline, however, was found to decrease yields, e.g. *N*-(2,6-dimethylphenyl)anthranilic acid, **13**, was obtained in only 65% (Table 3, entry 6). Coupling of 1-aminonaphthalene or 1-aminopyrene gave the corresponding products **21** and **23** in 96% and 73% yields (Table 3, entries 10 and 11). Importantly, no significant electronic effects were observed in the reaction of substituted anilines and chlorobenzoic acids. For example, amination of **1** with 4-methoxyaniline, **24**, and 4-nitroaniline, **26**, proceeded with 84% and 87%, respectively, and electron-deficient chlorobenzoic acid **32** gave anthranilic acid **33** in 99% yield (Table 3, entries 12, 13 and 16). The copper-catalyzed amination was found to proceed with high regio- and chemoselectivity. Amination only occurs when the halide is located in *ortho*-position to the carboxylic acid moiety. For example, coupling of 2,4-dichlorobenzoic acid, **34**, with 4-methoxyaniline, **24**, gave anthranilic acid **35** in 86% and amination of 5-bromo-2-chlorobenzoic acid, **36**, produced **37** in 85% yield (Table 3, entries 17 and 18). Aryl halide bonds located in the aniline moiety are also not affected. The coupling reaction between 2-chlorobenzoic acid and 3-chloroaniline,

28, gave **29** in 99% yield (Table 3, entry 14). The *ortho*-carboxylate group has been known to effectively accelerate homogeneous copper-catalyzed exchange reactions.¹⁷ Accordingly, our amination procedure affords high regioselectivity and tolerates various functionalities thus complementing other methods that allow effective amination of *meta*- and *para*-chlorobenzoic acids.

Carboxylic acids are known to form centrosymmetric dimers in solution and in the solid state in order to minimize the overall dipole moment.¹⁸ In the case of substituted *N*-aryl anthranilic acids, dimer formation could lead to two geometrical arrangements isolable in the solid state, namely *cis*- and probably favored *trans*-isomers exhibiting the *N*-aryl substituents on the same or on opposite sides. In addition, both *trans*- and *cis*-isomers could exhibit either *syn*- or *anti*-orientation having substituted *N*-aryl groups either pointing up or down relative to the anthranilic plane as shown for *N*-(2-methylphenyl)anthranilic acid, **3** (Figure 2).

Supramolecular isomerism has been defined as the existence of different types of crystal architectures produced from the same molecular building blocks and is closely related to molecular isomerism and polymorphism.¹⁹ The desire to understand and rationally design solid-state structures has resulted in remarkable advances in crystal engineering and supramolecular synthesis.²⁰ The possibility of four isomeric dimeric structures of anthranilic acids has led us to the study of solid-state conformational isomerism. We therefore employed appropriately substituted anthranilic acids **3**, **7**, **9**, **11**, **15**, **17**, **19**, **21**, and **29** in crystallization experiments. Through isothermal evaporation from methylene chloride solutions, we were able to grow single crystals of seven anthranilic acids (Figure 3). Anthranilic acids **3** and **11** formed monoclinic systems while the others gave triclinic crystals (Table 4). As expected, dimeric *N*-arylanthranilic acid structures were obtained in all cases. The dimeric arrangement of **3**, **7**, **9**, **11**, and **15** are of the centrosymmetric *trans-anti*-type. A pair of C=O...H-O hydrogen bonds and C=O...H-N hydrogen forces both anthranilic rings into the same plane. The unit cell of the single crystal of **3** contains eight molecules forming four centrosymmetric dimers (Figure 4). Through a Cambridge Structural Database (CSD) search we found five additional *N*-phenylanthranilic acid derivatives showing acid dimers with the same *trans-anti*-arrangement in the solid state.²¹

The dihedral angle, α , between the 2-methylphenyl moiety and the anthranilic ring of **3** was determined as 49.1° (Figure 5). Changing the *ortho*-substituent from methyl to *iso*-propyl, *tert*-butyl and phenyl did not affect the supramolecular architecture and molecular isomerism. However, the dihedral angle, α , was found to change from 49.1° (**3**) to 62.5° (**7**), 62.8° (**9**) and 77.1° (**11**) (Figure 5). While the dihedral angle increases with the bulkiness of the *ortho*-substituent, the almost perpendicular arrangement of the phenyl group is stabilized by additional π - π interactions between adjacent dimers (supporting information).

The *trans-anti*-dimers of **3**, **7**, **11**, and **15** show one-dimensional π - π interactions between the anthranilic aromatic rings (Figure 6). Anthranilic acid **3** formed π -stacking rods with a closest contact distance of 3.46 Å. Anthranilic acids **7**, **11**, and **15** have a similar packing arrangement and the corresponding closest contact distance was determined as 3.50 Å, 3.40 Å, and 3.46 Å, respectively. However, the bulky *tert*-butyl group of anthranilic **9** impedes effective π -stacking which is replaced by van der Waals interactions (supporting information).

Surprisingly, anthranilic acids **17** and **19** crystallized as non-centrosymmetric *trans-syn*-dimers (Figure 5). The conformational isomerism is accompanied by a quite distinct crystal architecture. In contrast to formation of π -stacking rods observed with anthranilic acids **3**, **7**, **11**, and **15**, the crystals of **17** and **19** show one-dimensional chains stabilized by π - π -interactions between the *tert*-butylphenyl and 3,5-dimethylbiphenyl rings, respectively. For example, the solid-state structure of anthranilic acid **17** has a closest contact between the *tert*-butylphenyl

rings of 3.48 Å (Figure 7). The π -stacking of the *trans-syn*-dimers results in infinite chains along the *b* axis. Empty space within one chain is filled with a complementary chain thus providing one-dimensional intertwined rods. The unexpected solid-state structures of the anthranilic acids studied resemble supramolecular conformational isomerism. While the crystal structures of acids **3**, **7**, **9**, **11**, and **15** show a previously reported packing motif exhibiting *trans-anti*-dimers, anthranilic acids **17** and **19** crystallized as dimeric *trans-syn*-conformers providing an unprecedented supramolecular architecture.

Conclusion

We have developed a highly regioselective Cu/Cu₂O-catalyzed cross-coupling reaction for effective C-N bond formation with 2-chlorobenzoic acids and aniline derivatives. The reaction complements existing methods, tolerates a variety of functional groups and gives high to excellent yields with both electron-deficient and electron-rich reagents. Crystallographic analysis of seven substituted *N*-aryl anthranilic acids showed two distinct supramolecular structures due to formation of *trans-anti*- and *trans-syn*-dimers in the solid state.

Experimental Section

General procedure for the Cu-catalyzed amination of aryl halides

A mixture of aniline (9.30 mmol), aryl halide (8.83 mmol), K₂CO₃ (8.83 mmol), Cu powder (0.78 mmol), and Cu₂O (0.35 mmol) in 3 mL of 2-ethoxyethanol was refluxed at 130°C under inert atmosphere for 24 hours. The cooled reaction mixture was poured into 30 mL of water. Charcoal was then added and the solution was filtered through celite. The crude product was obtained by precipitation upon acidification of the filtrate with diluted HCl. The residue was dissolved in 100 mL of 5 % aqueous Na₂CO₃ solution, filtered through celite and the final product was isolated by precipitation upon careful pH adjustment.

N-(2-Methylphenyl)anthranilic acid (**3**).^{12a}

Compound **3** was obtained from 2-chlorobenzoic acid, **1**, and 2-methylaniline, **2**, as an off-white powder in 92% yield. ¹H-NMR (300 MHz, CDCl₃) δ = 2.29 (s, 3H), 6.72 (bs, 1H), 6.85 (d, *J* = 8.2 Hz, 1H), 7.12 (dd, *J* = 7.2 Hz, 7.4 Hz, 1H), 7.20–7.34 (m, 5H), 8.05 (d, *J* = 7.2 Hz, 1H), 9.18 (bs, 1H). ¹³C-NMR (75 MHz, DMSO-*d*₆) δ = 17.6, 113.4, 116.9, 122.6, 124.0, 126.6, 130.9, 131.3, 134.0, 138.7, 148.6.

N-Phenylanthranilic acid (**5**).²²

Anthranilic acid **5** was obtained from 2-chlorobenzoic acid, **1** and aniline, **4** as a white solid in 83% yield. ¹H-NMR (300 MHz, CDCl₃) δ = 6.75 (dd, *J* = 7.9 Hz, 8.3 Hz, 1H), 7.13 (dd, *J* = 7.3 Hz, 8.6 Hz, 1H), 7.20–7.50 (m, 5H), 8.05 (d, *J* = 7.6 Hz, 1H), 9.33 (bs, 1H). ¹³C-NMR (75 MHz, CDCl₃) δ = 111.0, 114.7, 117.8, 123.8, 124.7, 130.0, 133.2, 135.8, 140.9, 149.5, 174.3.

N-(2-Isopropylphenyl)anthranilic acid (**7**).^{12a}

Amination of 2-chlorobenzoic acid, **1**, and 2-isopropylaniline, **6**, gave anthranilic acid **7** as a white powder in 73% yield. ¹H-NMR (300 MHz, CDCl₃) δ = 1.22 (d, *J* = 6.9 Hz, 6H), 3.21 (sept, *J* = 6.9 Hz, 1H), 4.68 (bs, 1H), 6.68 (dd, *J* = 7.2 Hz, 7.4 Hz, 1H), 6.81 (d, *J* = 8.2 Hz, 1H), 7.22–7.40 (m, 4H), 8.1 (dd, *J* = 1.7 Hz, 8.2 Hz, 1H), 9.18 (bs, 1H). ¹³C-NMR (75 MHz, DMSO-*d*₆) δ = 23.6, 28.4, 112.0, 113.6, 117.0, 125.7, 126.1, 127.1, 127.3, 132.5, 135.0, 137.9, 143.6, 149.8, 171.0.

***N*-(2-*tert*-Butylphenyl)anthranilic acid (9).²³**

Anthranilic acid **9** was produced from 2-chlorobenzoic acid, **1**, and 2-*tert*-butylaniline, **8**, as white crystals in 86% yield. ¹H-NMR (300 MHz, CDCl₃) δ = 1.41 (s, 9H), 6.65 (dd, *J* = 7.0 Hz, 7.9 Hz, 1H), 7.15 (d, *J* = 8.6 Hz, 1H), 7.17–7.28 (m, 4H), 7.47–7.50 (m, 1H), 8.02 (d, *J* = 8.1 Hz, 1H), 9.21 (bs, 1H). ¹³C-NMR (75 MHz, CDCl₃) δ = 31.3, 35.7, 110.0, 114.8, 116.7, 126.6, 127.6, 128.1, 129.8, 133.1, 135.9, 139.4, 147.1, 151.4, 173.7.

***N*-(2-Biphenyl)anthranilic acid (11).²⁴**

Acid **11** was obtained from 2-chlorobenzoic acid, **1**, and 2-aminobiphenyl, **10**, as a white solid in 85% yield. ¹H-NMR (300 MHz, CDCl₃) δ = 4.74 (bs, 1H), 6.72 (dd, *J* = 7.2 Hz, 7.7 Hz, 1H), 7.20–7.52 (m, 11H), 7.94 (d, *J* = 8.3 Hz, 1H), 9.18 (bs, 1H). ¹³C-NMR (75 MHz, CDCl₃) δ = 111.4, 114.7, 117.7, 123.7, 124.8, 128.0, 128.6, 129.0, 129.7, 131.7, 133.1, 135.6, 136.9, 138.2, 139.5, 149.3, 174.2.

***N*-(2,6-Dimethylphenyl)anthranilic acid (13).²⁵**

Amination of 2-chlorobenzoic acid, **1**, and 2,6-dimethylaniline, **12**, afforded acid **13** as a white powder in 65% yield. ¹H-NMR (300 MHz, CDCl₃) δ = 2.21 (s, 6H), 6.22 (d, *J* = 8.5 Hz, 1H), 6.66 (dd, *J* = 7.1 Hz, 7.1 Hz, 1H), 7.10–7.20 (m, 3H), 7.24 (dd, *J* = 7.6 Hz, 7.8 Hz, 1H), 8.04 (d, *J* = 7.6 Hz, 1H), 8.88 (bs, 1H). ¹³C-NMR (75 MHz, CD₃OD) δ = 18.5, 112.0, 115.7, 126.3, 128.3, 132.8, 134.1, 135.6, 135.9, 137.0, 149.9, 173.8.

***N*-(3-Methylphenyl)anthranilic acid (15).²⁵**

Compound **15** was obtained from 2-chlorobenzoic acid, **1**, and 3-methylaniline, **14**, as a white solid in 80% yield. ¹H-NMR (300 MHz, CDCl₃) δ = 2.39 (s, 3H), 6.79 (bs, 1H), 6.97 (d, *J* = 7.31 Hz, 1H), 7.00–7.15 (m, 2H), 7.25–7.30 (m, 2H), 7.38 (m, 1H), 8.10 (m, 1H), 9.25 (bs, 1H). ¹³C-NMR (75 MHz, DMSO-*d*₆) δ = 21.0, 113.9, 117.3, 118.3, 122.0, 123.8, 129.2, 132.5, 134.0, 138.9, 140.5, 147.5.

***N*-(3-*tert*-Butylphenyl)anthranilic acid (17)**

Acid **17** was produced by amination of 2-chlorobenzoic acid, **1**, and 3-*tert*-butylaniline, **16**, as a white solid in 85% yield. ¹H NMR(300 MHz, CDCl₃) δ = 1.34 (s, 9H), 6.74 (dd, *J* = 0.7 Hz, 7.4 Hz, 1H), 7.10 (d, *J* = 7.3 Hz, 1H), 7.16–7.37 (m, 5H), 8.05 (dd, *J* = 1.5 Hz, *J* = 8.1 Hz, 1H), 9.29 (bs, 1H). ¹³C-NMR(75 MHz, DMSO-*d*₆) δ = 31.0, 34.4, 112.4, 113.5, 117.2, 118.7, 118.9, 120.3, 129.0, 132.0, 134.1, 140.1, 147.4, 152.2, 170.1. Anal. calcd. for C₁₇H₂₀ClNO₂: C, 66.77; H, 6.59; N, 4.58. Found: C, 67.27; H, 7.16; N, 4.93. (The HCl salt was formed by addition of hydrogen chloride (diethyl ether, 2.0 M) for elemental analysis.)

***N*-[3-(3',5'-Dimethylbiphenyl)]anthranilic acid (19).²⁶**

Anthranilic acid **19** was obtained from 2-chlorobenzoic acid, **1**, and 3-amino-3',5'-dimethylbiphenyl, **18**, as an off-white solid in 99% yield. ¹H-NMR (300 MHz, CDCl₃) δ = 2.39 (s, 6H), 4.43 (s, 2H), 6.77 (dd, *J* = 7.1 Hz, 7.6 Hz, 1H), 7.02 (s, 1H), 7.22–7.50 (m, 8H), 8.06 (d, *J* = 8.0 Hz, 1H). ¹³C-NMR (75 MHz, CDCl₃) δ = 21.7, 113.7, 114.4, 115.9, 117.5, 121.9, 122.1, 123.1, 125.2, 128.7, 129.3, 129.8, 133.9, 135.3, 138.5, 140.9, 143.0, 149.1. Anal. calcd. for C₂₁H₁₉NO₂: C, 79.50; H, 5.99; N, 4.42. Found: C, 79.10; H, 6.23; N, 4.32.

***N*-(1-Naphthyl)anthranilic acid (21).²⁷**

Anthranilic acid **21** was obtained from 2-chlorobenzoic acid, **1** and 1-aminonaphthalene, **20**, as an off-white solid in 96% yield. ¹H-NMR (300 MHz, CDCl₃) δ = 6.73 (dd, *J* = 7.3 Hz, 7.6 Hz, 1H), 6.85(d, *J* = 8.6 Hz, 1H), 7.23–7.29 (m, 1H), 7.46–7.51 (m, 4H), 7.75 (d, *J* = 7.6 Hz, 1H), 7.89–7.92 (m, 1H), 8.08(m, 2H), 9.60 (bs, 1H). ¹³C-NMR (75 MHz, CDCl₃) δ = 110.5,

114.2, 117.5, 122.8, 123.5, 126.5, 126.5, 127.1, 129.1, 130.8, 133.1, 135.5, 136.0, 136.9, 151.2, 174.2.

***N*-(1-Pyrenyl)anthranilic acid (23)**

Amination of 2-chlorobenzoic acid, **1**, and 1-aminopyrene, **22**, afforded anthranilic acid **23** as an off-white solid in 73% yield. ¹H NMR (300 MHz, DMSO-*d*₆) δ = 6.94 (dd, *J* = 7.4 Hz, 7.4 Hz, 1H), 7.14 (d, *J* = 8.3 Hz, 1H), 7.43 (dd, *J* = 8.0 Hz, 7.4 Hz, 1H), 8.09–8.41 (m, 10H), 10.7 (bs, 1H). ¹³C NMR (75 MHz, DMSO-*d*₆): δ = 114.2, 118.1, 122.0, 122.1, 124.8, 124.9, 125.4, 125.7, 125.8, 126.4, 126.7, 127.2, 128.0, 128.2, 131.4, 131.7, 133.6, 134.6, 135.2, 148.8, 172.7. Anal. calcd. for C₂₃H₁₅NO₂: C, 81.88; H, 4.48; N, 4.15. Found: C, 81.63; H, 4.74; N, 4.32.

***N*-(4-Methoxyphenyl)anthranilic acid (25).¹⁶**

Anthranilic acid **25** was obtained from 2-chlorobenzoic acid, **1**, and 4-methoxyaniline, **24**, as a white powder in 84% yield. ¹H-NMR (300 MHz, CDCl₃) δ = 3.83 (s, 3H), 6.68 (dd, *J* = 7.3 Hz, 7.3 Hz, 1H), 6.93 (dd, *J* = 8.6 Hz, 8.6 Hz 3H), 7.18 (d, *J* = 8.6 Hz, 2H), 7.26–7.32 (m, 1H), 8.0 (d, *J* = 8.6 Hz, 1H), 9.60 (bs, 1H). ¹³C-NMR (75 MHz, DMSO-*d*₆) δ = 55.2, 111.4, 112.8, 114.8, 116.3, 125.1, 131.9, 133.0, 134.2, 148.9, 156.1, 170.2.

***N*-(4-Nitrophenyl)anthranilic acid (27).¹⁶**

Anthranilic acid **27** was produced from 2-chlorobenzoic acid, **1**, and 4-nitroaniline, **26**, as a yellow solid in 87% yield. ¹H-NMR (300 MHz, CD₃OD) δ = 7.22 (dd, *J* = 7.1 Hz, 7.8 Hz, 1H), 7.50 (m, 2H), 7.68–7.78 (m, 2H), 8.26 (d, *J* = 8.1 Hz, 1H), 8.36–8.36 (m, 2H). ¹³C-NMR (75 MHz, CD₃OD) δ = 118.1, 118.2, 118.8, 122.2, 127.1, 133.7, 135.3, 142.6, 145.4, 150.0, 171.5.

***N*-(3-Chlorophenyl)anthranilic acid (29).²⁸**

Amination of 2-chlorobenzoic acid, **1** and 3-chloroaniline, **28**, gave anthranilic acid **29**, as an off-white solid in 99% yield. ¹H-NMR (300 MHz, CDCl₃) δ = 6.82 (dd, *J* = 7.3 Hz, 7.6 Hz, 1H), 7.08 (d, *J* = 7.8 Hz, 1H), 7.14 (d, *J* = 7.8 Hz, 1H), 7.26–7.30 (m, 3H), 7.40 (dd, *J* = 7.6 Hz, 7.8 Hz, 1H), 8.06 (d, *J* = 7.3 Hz, 1H), 9.32 (bs, 1H). ¹³C-NMR (75 MHz, CDCl₃) δ = 114.2, 114.7, 118.5, 118.8, 119.9, 122.1, 130.9, 132.0, 133.9, 134.0, 142.6, 145.8, 169.9.

***N*-(4-Carboxyphenyl)anthranilic acid (31).²⁷**

Anthranilic acid **31** was obtained from 2-chlorobenzoic acid, **1**, and 4-aminobenzoic acid, **30**, using two equivalents of K₂CO₃ as a white solid in 98% yield. ¹H-NMR (300 MHz, CD₃OD) δ = 7.00–7.06 (m, 1H), 7.37 (d, *J* = 8.8 Hz, 2H), 7.56–7.59 (m, 2H), 7.98 (d, *J* = 8.8 Hz, 2H), 8.04 (d, *J* = 8.3 Hz, 1H), 9.91 (bs, 1H). ¹³C-NMR (75 MHz, CD₃OD) δ = 115.3, 116.2, 117.9, 119.6, 123.5, 131.2, 132.0, 134.1, 144.6, 145.6, 167.1, 169.7.

***N*-(4-Methoxyphenyl)-4-nitroanthranilic acid (33).²⁶**

Anthranilic acid **33** was obtained from 2-chloro-4-nitrobenzoic acid, **32**, and 4-methoxyaniline, **24**, as a yellow solid in 99% yield. ¹H-NMR (300 MHz, CD₃OD) δ = 3.98 (s, 3H), 5.07 (bs, 1H), 7.05–7.20 (m, 3H), 7.32 (d, *J* = 8.5 Hz, 2H), 7.40 (d, *J* = 8.8 Hz, 1H), 8.05 (s, 1H). ¹³C-NMR (75 MHz, CD₃OD:DMSO-*d*₆ = 10:1) δ = 55.0, 116.1, 116.2, 121.6, 126.7, 126.9, 132.5, 134.4, 135.3, 149.8, 158.6, 170.6.

***N*-(4-Methoxyphenyl)-4-chloroanthranilic acid (35).²⁶**

Compound **35** was produced from 2,4-dichlorobenzoic acid, **34**, and 4-methoxyaniline, **24**, as an off-white powder in 86% yield. ¹H-NMR (300 MHz, CDCl₃) δ = 3.83 (s, 3H), 6.87 (d, *J* = 9.2 Hz, 1H), 6.92 (d, *J* = 8.9 Hz, 2H), 7.15 (d, *J* = 8.9 Hz, 2H), 7.19–7.24 (m, 1H), 7.95 (d, *J*

= 2.5 Hz, 1H), 9.05 (bs, 1H). ^{13}C -NMR (75 MHz, CDCl_3) δ = 56.2, 111.52, 115.4, 121.2, 126.9, 132.1, 133.1, 133.5, 135.5, 149.5, 157.7, 173.1.

***N*-(4-Methoxyphenyl)-4-bromoanthranilic acid (37)**

Amination of 4-bromo-2-chlorobenzoic acid, **36**, and 4-methoxyaniline, **24**, afforded anthranilic acid **37** as an off-white solid in 85% yield. ^1H -NMR (300 MHz, CDCl_3) δ = 3.83 (s, 3H), 6.82 (d, J = 9.0 Hz, 1H), 6.92 (d, J = 8.5 Hz, 2H), 7.15 (d, J = 8.5 Hz, 2H), 7.30–7.35 (m, 1H), 8.10 (s, 1H), 9.10 (bs, 1H). ^{13}C -NMR (75 MHz, $\text{DMSO}-d_6$) δ = 55.8, 113.5, 115.4, 120.1, 125.8, 131.4, 133.3, 133.7, 134.2, 148.3, 157.0, 169.8. Anal. calcd. for $\text{C}_{14}\text{H}_{12}\text{BrNO}_3$: C, 52.20; H, 3.75; N, 4.35. Found: C, 52.08; H, 3.72; N, 4.78.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

Funding from the National Science Foundation (CAREER Award, Grant CHE-0347368) and the donors of the Petroleum Research Fund, administered by the American Chemical Society (Grant PRF40897-G4), is gratefully acknowledged.

References and Notes

- (a) Lindley J. *Tetrahedron* 1984;40:1433–1456. (b) Subramanian V, Batchu VR, Barange D, Pal M. *J Org Chem* 2005;70:4778–4783. [PubMed: 15932318] (c) Klapars A, Parris S, Anderson KW, Buchwald SL. *J Am Chem Soc* 2004;126:3529–3533. [PubMed: 15025480] (d) Beletskaya IP, Bessmertnykh AG, Averin AD, Denat F, Guillard R. *Eur J Org Chem* 2005:281–305.
- (a) Hamann BC, Hartwig JF. *J Am Chem Soc* 1998;120:7369–7370. (b) Hartwig JF, Kawatsura M, Hauck SI, Shaughnessy KH, Alcazar-Roman LM. *J Org Chem* 1999;64:5575–5580. [PubMed: 11674624] (c) Wolfe JP, Buchwald SL. *J Org Chem* 1997;62:6066–6068. (d) Old DW, Wolfe JP, Buchwald SL. *J Am Chem Soc* 1998;120:9722–9723. (e) Hartwig JF. *Angew Chem, Int Ed Engl* 1998;37:2046–2067. (f) Wolfe JP, Wagaw S, Marcoux JF, Buchwald SL. *Acc Chem Res* 1998;31:805–818.
- (a) Gajare AS, Toyota K, Yoshifuji M, Ozawa F. *Chem Comm* 2004:1994–1995. [PubMed: 15340638] (b) Ferreira ICFR, Queiroz MJRP, Kirsch G. *Tetrahedron* 2002;58:7943–7949. (c) Gujadhur RK, Bates CG, Venkataraman D. *Org Lett* 2001;42:4791–4793. (d) Goodbrand HB, Hu NX. *J Org Chem* 1999;64:670–674.
- Klapars A, Huang X, Buchwald SL. *J Am Chem Soc* 2002;124:7421–7428. [PubMed: 12071751]
- (a) Son SU, Park IK, Park J, Hyeon T. *Chem Comm* 2004:778–779. (b) Choudary BM, Sridhar C, Kantam ML, Venkanna GT, Sreedhar B. *J Am Chem Soc* 2005;127:9948–9949. [PubMed: 16011328]
- (a) Klapars A, Antilla JC, Huang X, Buchwald SL. *J Am Chem Soc* 2001;123:7727–7729. [PubMed: 11481007] (b) Zhang H, Cai Q, Ma D. *J Org Chem* 2005;70:5164–5173. [PubMed: 15960520]
- Job GE, Buchwald SL. *Org Lett* 2002;4:3703–3706. [PubMed: 12375923]
- (a) Okano K, Tokuyama H, Fukuyama T. *Org Lett* 2003;5:4987–4990. [PubMed: 14682746] (b) Kwong FY, Buchwald SL. *Org Lett* 2003;5:793–796. [PubMed: 12633073] (c) Ma D, Cai Q, Zhang H. *Org Lett* 2003;5:2453–2455. [PubMed: 12841753] (d) Lu Z, Twieg RJ, Huang SD. *Tetrahedron Lett* 2003;44:6289–6292. (e) Maes BUW, Loones KTJ, Hostyn S, Diels G, Rombouts G. *Tetrahedron* 2004;60:11559–11564. (f) Ezquerra J, Pedregal C, Lamas C, Barluenga J, Perez M, Garcia-Martin MA, Gonzalez JM. *J Org Chem* 1996;61:5804–5812. (g) Cacchi S, Fabrizi G, Goggiani A, Zappia G. *Org Lett* 2001;3:2539–2541. [PubMed: 11483055] (h) Artamkina GA, Sergeev AG, Beletskaya IP. *Tetrahedron Lett* 2001;42:4381–4394.
- Ullmann F. *Ber dt chem Ges* 1903;36:2382–2384.
- (a) Hanoun JP, Tensglia A. *Synth Commun* 1995;25:2443–2448. (b) Docampo Palacios ML, Pellon Comdom RF. *Synth Commun* 2003;33:1771–1775.

11. (a) Wolf C, Mei X. *J Am Chem Soc* 2003;125:10651–10658. [PubMed: 12940749] (b) Mei X, Wolf C. *J Org Chem* 2005;70:2299–2305. [PubMed: 15760218] (c) Mei X, Wolf C. *J Am Chem Soc* 2004;126:14736–14737. [PubMed: 15535695] (d) Mei X, Wolf C. *Chem Comm* 2004:2078–2079. [PubMed: 15367983]
12. (a) Oza VB, Petrassi HM, Purkey HE, Kelly JW. *Bioorg Med Chem Lett* 1999;9:1–6. [PubMed: 9990446] (b) Green NS, Palaninathan SK, Sacchetti JC, Kelly JW. *J Am Chem Soc* 2003;125:13404–13414. [PubMed: 14583036] (c) Oza VB, Smith C, Raman B, Koepf EK, Lashuel HA, Petrassi HM, Chiang KP, Powers ET, Sacchetti J, Kelly JW. *J Med Chem* 2002;45:321–332. [PubMed: 11784137] (d) Baures PW, Oza VB, Peterson SA, Kelly JW. *Bioorg Med Chem* 1999;7:1339–1347. [PubMed: 10465408] (e) Klabunde T, Petrassi HM, Oza VB, Raman P, Kelly JW, Sacchetti JC. *Nature Struct Biol* 2000;7:312–321. [PubMed: 10742177]
13. (a) Girault S, Grellier P, Berecibar A, Maes L, Mouray E, Lemiere P, Debeu MA, Davioud-Charvet E, Sergheraert C. *J Med Chem* 2000;43:2646–4654. [PubMed: 10893302] (b) Demeunynck M, Charmantray F, Martelli A. *Curr Pharm Des* 2001;7:1703–1724. [PubMed: 11562307] (c) Brana MF, Cacho M, De Pascual-Teresa B, Ramos A. *Curr Pharm Des* 2001;7:1745–1780. [PubMed: 11562309] (d) Cain BF, Seelye RN, Atwee GJ. *J Med Chem* 1974;17:922–928. [PubMed: 4415157]
14. Huang X, Anderson KW, Zim D, Jiang L, Klapars A, Buchwald SL. *J Am Chem Soc* 2003;125:6653–6655. [PubMed: 12769573]
15. Kwong FY, Klapars A, Buchwald SL. *Org Lett* 2002;4:581–584. [PubMed: 11843596]
16. Csuk R, Barthel A, Raschke C. *Tetrahedron* 2004;60:5737–5750.
17. Couture C, Paine AJ. *Can J Chem* 1985;63:111–120.
18. Desiraju GR. *Angew Chem, Int Ed Engl* 1995;34:2311–2327.
19. (a) Moulton B, Zaworotko MJ. *Chem Rev* 2001;101:1629–1658. [PubMed: 11709994] (b) Swift JA, Pivovar AM, Reynolds AM, Ward MD. *J Am Chem Soc* 1998;120:5887–5894.
20. Desiraju, GR. *Crystal Engineering: The Design of Organic Solids*. Elsevier; Amsterdam: 1989. (b) Reddy DS, Craig DC, Desiraju GR. *J Am Chem Soc* 1996;118:4090–4093. (c) Desiraju GR. *Acc Chem Res* 2002;35:565–573. [PubMed: 12118996] (d) Gavezzotti A. *Acc Chem Res* 1994;27:309–314.
21. *N*-(2-Methoxyphenyl)anthranilic acid, *N*-(2-carboxyphenyl)anthranilic acid, *N*-(2'-carboxy-5'-chlorophenyl)-4-chloroanthranilic acid, *N*-(2-methyl-3-chlorophenyl)anthranilic acid and *N*-(3-methyl-2,6-dichlorophenyl)anthranilic acid.
22. Scherrer RA, Beatty HR. *J Org Chem* 1980;45:2127–2131.
23. Denny WA, Twigden SJ, Baguley BC. *Anti-Cancer Drug Des* 1986;1:125–132.
24. Graboyes H, Anderson EL, Levinson SH, Resnick TM. *J Heterocyclic Chem* 1975;12:1225–1231.
25. Thilo D, Von Kaulla KN. *J Med Chem* 1970;13:503–510. [PubMed: 5441134]
26. Dokorou V, Demertzis MA, Jasinski JP, Kovala-Demertzi DJ. *Organomet Chem* 2004;689:317–325.
27. Szczepankiewicz BG, Liu G, Hajduk PJ, Abad-Zapatero C, Pei Z, Xin Z, Lubben TH, Trevillyan JM, Stashko MA, Ballaron SJ, Liang H, Huang F, Hutchins CW, Fesik SW, Jirousek MR. *J Am Chem Soc* 2003;125:4087–4096. [PubMed: 12670229]
28. Dheyongera JP, Geldenhuys WJ, Dekker TG, Van der Schyf CJ. *Bioorg Med Chem* 2005;13:689–698. [PubMed: 15653336]

flufenamic acid

mefenamic acid

Figure 1.

Structures of anthranilic acid derivatives used as NSAIDs and for the treatment of amyloidogenic diseases.

Figure 2.
Possible arrangements of dimers of **3**.

Figure 3.
Structures of *N*-phenylanthranilic acid derivatives employed in single crystal analysis.

Figure 4.

ORTEP perspectives of anthranilic acid derivatives: (a) *N*-(2-methylphenyl)anthranilic acid **3** and (b) *N*-(3-*tert*-butylphenyl)anthranilic acid **17**. Selected interatomic distances [Å] and angles [°]: (a) O(1)···O(2) 2.224, N(1)···O(1) 2.636, O(2)-H(2')···O(1) 172.79, N(1)-H(1)···O(1) 138.32; (b) O(1)···O(3) 2.643, O(2)···O(4) 2.707, N(1)···O(2) 2.733, N(2)···O(3) 2.692, O(4)-H(4O)···O(2) 164.42, N(1)-H(1)···O(2) 132.77.

Figure 5.
X-ray crystal structures of anthranilic acid **3**, **7**, **9**, **11**, **15**, **17**, and **19** exhibiting *trans-anti*- (left) and *trans-syn*-dimeric conformations (right).

Figure 6. One-dimensional π -stacking of anthranilic acid **3** (top) and schematic illustration of the *trans-anti*-dimers and packing motif (bottom).

Figure 7. Formation of intertwined rods in the crystal structure of anthranilic acid **17** (top) and schematic illustration of the packing of the *trans-syn*-dimers (bottom).

Table 1Copper-catalyzed amination of 2-chlorobenzoic acid^a

entry	catalyst (mol %)	reaction time (h)	yield (%) ^b
1	CuI (4%)	24	55
2	Cu ₂ O (4%)	24	56
3	Cu (9%)	24	55
4	Cu (9%), CuI (4%)	24	51
5	Cu (9%), Cu ₂ O (4%)	24	76
6	Cu (12%), Cu ₂ O (4%)	5	66
7	Cu (9%), Cu ₂ O (4%)	5	71
8	Cu (6%), Cu ₂ O (4%)	5	51
9	Cu (4%), Cu ₂ O (4%)	5	51

^a Reaction conditions: 2-Chlorobenzoic acid (1.38 g, 8.83 mmol), 1.05 equiv. of 2-methylaniline, 2.0 equiv. of potassium carbonate in 3 mL of 2-ethoxyethanol at 130°C.

^b Isolated yields.

Table 2

Screening of solvents and bases^a

entry	base	solvent	T (°C)	yield (%) ^b
1	K ₂ CO ₃	<i>n</i> -butanol	117	75
2	K ₂ CO ₃	water	100	35
3	K ₂ CO ₃	ethylene glycol	130	40
4	K ₂ CO ₃	2-ethoxyethanol	130	76
5	K ₂ CO ₃	diethylene glycol	130	90
6	Cs ₂ CO ₃	diethylene glycol	130	5
7	Na ₂ CO ₃	diethylene glycol	130	82
8	<i>tert</i> -BuOK	diethylene glycol	130	11
9	K ₃ PO ₄	diethylene glycol	130	70
10	NaOAc	diethylene glycol	130	66
11	TMP	diethylene glycol	130	30
12	Na ₂ CO ₃	2-ethoxyethanol	130	92 ^d
13	K ₂ CO ₃	2-ethoxyethanol	130	75 ^c
14	K ₂ CO ₃	2-ethoxyethanol	130	83, ^{cd}

^a Reaction conditions: 2-Chlorobenzoic acid (1.38 g, 8.83 mmol), 1.05 equiv. of 2-methylaniline, 9 mol% of Cu, 4 mol% of Cu₂O, 2.0 equiv. of base, 3 mL of solvents, 130°C for 24 hours.

^b Isolated yields.

^c Aniline was used.

^d 1.0 equiv. of base was used.

Table 3

Arylation of aryl chlorides with aryl amines^a

entry	aryl chloride	amine	product	Yield (%) ^b
1	1	4	5	83
2	1	2	3	92 ^c
3	1	6	7	73
4	1	8	9	86
5	1	10	11	85
6	1	12	13	65
7	1	14	15	80
8	1	16	17	85

entry	aryl chloride	amine	product	Yield (%) ^b
9				99
10				96
11				73
12				84
13				87
14				99
15				98 ^d
16				99
17				86

entry	aryl chloride	amine	product	Yield (%) ^b
18	 36	 24	 37	85

^a Reaction conditions: 2-Chlorobenzoic acid (1.38 g, 8.83 mmol), 1.05 equiv. of amine, 1.0 equiv. of K₂CO₃, 9 mol% of Cu, 4 mol% of Cu₂O, 3 mL of 2-ethoxyethanol and 130°C for 24 hours.

^b Isolated yields.

^c Na₂CO₃ was used as base.

^d 2.0 equiv. of base were used

Table 4

Crystallographic parameters of anthranilic acid derivatives

compound name	3	7	9	11	15	17	19
formula	C ₁₄ H ₁₃ NO ₂	C ₁₆ H ₁₇ NO ₂	C ₁₇ H ₁₉ NO ₂	C ₁₉ H ₁₅ NO ₂	C ₁₄ H ₁₃ NO ₂	C ₁₇ H ₁₉ NO ₂	C ₂₁ H ₁₉ NO ₂
mol wt	227.25	255.31	269.33	289.32	227.25	269.33	317.37
temp (K)	173	183	173	183	173	163	173
system	Monoclinic	Triclinic	Triclinic	Monoclinic	Triclinic	Triclinic	Triclinic
space group	C2/c	P-1	P-1	P2 ₁ /c	P-1	P-1	P-1
a (Å)	11.7804(16)	7.4585(10)	7.4748(12)	5.7231(8)	4.6299(14)	10.9634(7)	10.5769(16)
b (Å)	7.4503(10)	7.5891(10)	9.3856(15)	17.929(2)	8.332(2)	11.7048(7)	11.4108(17)
c (Å)	26.627(3)	13.6653(19)	11.0319(17)	14.4300(19)	15.336(4)	22.9688(14)	14.162(2)
α(°)	90	79.998(2)	106.582(3)	90°	98.466(4)	88.8990(10)	80.856(3)
β(°)	100.168(2)	85.875(2)	91.207(3)	101.064(2)	92.198(4)	89.0970(10)	82.334(3)
γ(°)	90	62.141(2)	99.212(3)	90	101.337(4)	82.0050(10)	84.982(3)
V (Å ³)	2300.3(5)	673.42(16)	730.4(2)	1453.2(3)	572.3(3)	2918.0(3)	1668.5(4)
Z	8	2	2	4	2	8	4
ρ (g/cm ³)	1.312	1.259	1.225	1.322	1.319	1.226	1.263
θ range (°)	1.55–27.99	1.51–27.99	1.93–28.00	1.83–27.99	2.52–28.00	1.76–28.00	1.95–27.99
index ranges	–15 ≤ h ≤ 15 –9 ≤ k ≤ 9 –35 ≤ l ≤ 34	–9 ≤ h ≤ 9 –9 ≤ k ≤ 10 –17 ≤ l ≤ 18	–9 ≤ h ≤ 9 –12 ≤ k ≤ 12 –14 ≤ l ≤ 14	–7 ≤ h ≤ 7 –23 ≤ k ≤ 22 –18 ≤ l ≤ 19	–76 ≤ h ≤ 6 –10 ≤ k ≤ 11 –20 ≤ l ≤ 19	–14 ≤ h ≤ 14 –15 ≤ k ≤ 15 –30 ≤ l ≤ 29	–13 ≤ h ≤ 13 –14 ≤ k ≤ 14 –18 ≤ l ≤ 18
reflns collected	9959	6018	6614	12467	4861	25329	14927
unique reflns	2714	3054	3338	3401	2552	13122	7547
R(int)	0.0410	0.0282	0.0231	0.0430	0.0211	0.0345	0.0309
refined params	155	174	192	199	155	733	445
GOF on F ²	1.020	0.914	1.060	1.027	0.980	1.045	1.032
R ₁ [I>2σ(I)]	0.0483	0.0462	0.0414	0.0463	0.0442	0.0618	0.0460
wR2 (all data)	0.1409	0.1228	0.1073	0.1127	0.1140	0.2060	0.1154